UBS


Lincoln National: There’s A Lot More To The Story Than Interest Rates, Says UBS

In a research report issued Friday, UBS analyst Suneet Kamath assigned a Buy rating on Lincoln National (NYSE:LNC), and slightly raised his price …

UBS Remains Neutral On Coca-Cola Following New Equity Stewardship Guidelines

In a research note issued today to investors, UBS analyst Stephen Powers reiterated a Neutral rating on Coca-cola Company (NYSE:KO) with a $44 price target, as …

UBS Downgrades JP Morgan To Neutral; Sees No Sufficient Upside To PT

In a research report released today, UBS analyst Brennan Hawken downgraded shares of JP Morgan (NYSE:JPM) to a Neutral rating from a Buy …

UBS Maintains Neutral On Costco, Increases PT To $125

In a research report issued today, UBS analyst Jason DeRise maintained a Neutral rating on Costco Wholesale Corp. (NASDAQ:COST) and increased his price …

UBS Upgrades Bank Of America To Buy, Increases PT To $20

In a research report issued today, UBS analyst Brennan Hawken upgraded shares of Bank of America (NYSE:BAC) from a Hold to a Buy rating …

Nike Wows Investors With A Stellar Q1

Nike, Inc. (NYSE: NKE) is a Beaverton, Oregon based American multinational corporation that designs, develops, manufactures and sells athletic footwear, apparel, equipment and accessories …

UBS Reiterates Buy On Micron Technology, Increases PT To $36

In a research report released yesterday, UBS analyst Stephen Chin reiterated a Buy rating on Micron Technology (NASDAQ:MU) and increased his price target …

UBS Raises Trinity Price Target Following Investor Meetings With CFO

In a research note issued Friday, analyst Eric Crawford of UBS reiterated a Buy rating on Trinity Industries (NASDAQ:TRN) and raised his price target to $60 (from $55), …

We View Red Hat’s Stock As Reasonably Priced, Says UBS; Reduces PT To $68

In a report issued today to investors, UBS analyst Brent Thill reiterated a Buy rating on Red Hat (NYSE:RHT) and slightly raised his price target to …

Auxilium: We Are Moving To The Sidelines, Says UBS

In a research report issued today, UBS analyst Marc Goodman downgraded shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) to Neutral from Buy, but maintained his $31 price target. …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts